This article is more than 5 years old. Information may no longer be current.

NuMedii, Allergan partner on psoriasis research

NuMedii announced in a press release it has formed a research alliance with Allergan to evaluate new therapies in treating psoriasis.

NuMedii will provide Allergan with “proprietary, de-risked therapeutic candidates for psoriasis that are compatible with the 505b2 drug development regulatory pathway,” the release stated.

By utilizing its big data intelligence technology for psoriasis, NuMeddi has generated multiple lead compounds, which will be the focus in the research alliance, according to the release.

“We are excited to partner with Allergan to explore innovative treatments for the potential treatment of psoriasis,” Gini Deshpande, PhD, NuMedii’s CEO, stated in the release. “Allergan is an ideal research partner for NuMedii’s psoriasis program.”

The Palo Alto, Calif-based company did not release financial terms of the agreement.

NuMedii’s big data technology integrates human, biological, pharmacological and clinical data points with proprietary network-based algorithms to find drug candidates and biomarkers that predict efficacy for diseases, according to the release. The company is initially using the technology to discover and de-risk new indications for existing drugs, the release reported.

Reference: www.numedii.com